Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in pre-diagnostic breast cancer sera
Menée sur une cohorte initiale de 20 patientes atteintes d'un cancer du sein de stade III et 20 témoins, puis validée sur une cohorte de 33 cas et 45 témoins, cette étude évalue la faisabilité et l'intérêt de mesurer les niveaux sériques d'auto-anticorps dirigés contre HER2, p53, CEA et la cycline B1 pour la détection précoce d'un cancer du sein
Serum autoantibodies, directed against oncogenic proteins, have been frequently detected in the sera of breast cancer patients. It is unknown whether serum antibodies that are identified in patients with established disease could also be detected in patients with newly diagnosed disease or even predate the diagnosis of breast cancer. Using sera collected at the time of treatment, at the time of diagnosis, or prior to the time of diagnosis, the current study aimed to address the temporal relationship between breast cancer development and serum antibody response. Starting from serum antibodies to eight known breast cancer antigens, we first identified four serum antibodies, HER-2/neu, p53, CEA, and cyclin B1, which are significantly increased in the sera collected from breast cancer patients at the time of treatment. These antibodies were also elevated in breast cancer sera collected at the time of diagnosis. Lastly, comparison of antibody responses in pre-diagnostic samples from women prior to the development of breast cancer and in controls demonstrated that antibodies to the HER-2/neu and p53 can be detected in sera that were collected on average more than 150 days before a breast cancer diagnosis. These results demonstrated that serum autoantibodies commonly reported in sera from patients with established disease can also be detected in pre-diagnostic sera and may be useful for the early detection of breast cancer.
Cancer Prevention Research , résumé, 2012